Axsome Therapeutics, Inc. announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo represents a… read more.
Almost 50 million Americans—disproportionately in rural areas—must drive 25 miles or more to access a gastroenterologist for diagnosis and treatment of issues involving the digestive system, according to… read more.
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an updated version developed by researchers at the University of… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.
A meta-analysis evaluating bleeding risks among atrial fibrillation (AF) patients treated with therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) indicates that rates of major… read more.
Research from Saint Louis University (SLU) and the University of Nevada, Reno School of Medicine finds that some of the most-watched ads promote the worst food options for… read more.
Valneva SE reported further positive Phase III data in adolescents for its single-shot chikungunya virus (Chikv) vaccine, Ixchiq, which showed a sustained 98.3% sero-response rate one-year after single… read more.
New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for improved treatment. UTIs are one of the most prevalent… read more.
A national shortage in a common treatment for attention-deficit hyperactivity disorder was associated with changes in stimulant prescriptions filled for children over recent years, a new study suggests…. read more.
Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults… read more.
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.
Swedish pharmacy personnel report a deteriorating climate as regards patient safety, according to a study from the University of Gothenburg. Just under four in ten have a positive… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
